Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence
Our literature review underscores the intricate relationship between anticoagulation and ICIs in cancer therapy. Future studies should prioritize exploring the interactions between ICI, FXa inhibitors, and antiplatelet agents.
Authors
- Daniel J. Smit (ORCID: https://orcid.org/0000-0002-3190-9511)
- Christoffer Gebhardt (ORCID: https://orcid.org/0000-0001-7090-9584)
- Noah Zimmermann (ORCID: https://orcid.org/0009-0003-3837-1640)
- Stefan W. Schneider (ORCID: https://orcid.org/0000-0002-4679-7137)
- Tim Zell (ORCID: https://orcid.org/0009-0004-8096-7402)
- Julian Kött
- Alexander T Bauer
- Nina Matthes (ORCID: https://orcid.org/0009-0004-9004-1881)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Cancer Center Hamburg (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013879
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00